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PATHOGENESIS OF HYPERHOMOCYSTEINEMIA
OMOCYSTEINE is a non-protein-forming, sulfur amino acid whose metabolism is at the intersection of The more severe cases of hyperhomocysteinemia are two metabolic pathways 1 : remethylation and transsulfuration caused by homozygous defects in genes encoding for en- (Fig 1) . In remethylation, homocysteine acquires a methyl zymes of homocysteine metabolism. In such cases, a defect group from N-5-methyltetrahydrofolate (MTHF) or from bein an enzyme involved in either homocysteine remethylation taine to form methionine. The reaction with MTHF occurs or transsulfuration leads to large elevations of homocysteine in all tissues and is vitamin B12-dependent, whereas the in the blood and urine. The classic form of such a disorderreaction with betaine is confined mainly to the liver and congenital homocystinuria-is caused by homozygous deis vitamin B12-independent. A considerable proportion of fects in the gene encoding for CBS. In these individuals, methionine is then activated by adenosine triphosphate fasting plasma homocysteine concentrations can be as high (ATP) to form S-adenosylmethionine (SAM). SAM serves as 400 mmol/L. 4 Two different forms of the disease can be primarily as a universal methyl donor to a variety of acdistinguished on the basis of the responsiveness to treatment ceptors including guanidinoacetate, nucleic acids, neurowith large dosages of vitamin B6. 5, 6 Several CBS mutations transmitters, phospholipids, and hormones. S-adenosylhoare known [7] [8] [9] [10] : the most frequent are 833TC and 919GA, mocysteine (SAH), the byproduct of these methylation located in exon 8; and 1224-2AC, which causes the entirety reactions, is subsequently hydrolyzed, thus regenerating hoof exon 12 being deleted. The 833TC is spread in several mocysteine, which then becomes available to start a new ethnic groups; the 919GA mutation has been almost exclucycle of methyl-group transfer. In the transsulfuration sively reported in patients of Celtic origin. In 20 homocyspathway, homocysteine condenses with serine to form cystatinuric patients from 16 unrelated Italian families, characthionine in an irreversible reaction catalyzed by the pyriterization of 24 of 30 independent alleles disclosed 13 doxal-5-phosphate (PLP)-containing enzyme, cystathiomutations, including 11 novel mutations (146CT, 172CT, nine b-synthase (CBS). Cystathionine is hydrolyzed by a 262CT, 346GA, 374GA, 376AG, 452del27, 770CT, second PLP-containing enzyme, gamma-cystathionase, to 844ins68, 869CT, 904GA). Two previously reported mutaform cysteine and a-ketobutyrate. Excess cysteine is oxitions (833TC and 341CT) were found in 26.6% and 16.6% dized to taurine and inorganic sulfates or excreted in the of the alleles. Hence, most of the mutations are 'private' and urine. Thus, in addition to the synthesis of cysteine, this clustered on exons 8, 3, and 1. 9, 10 transsulfuration pathway effectively catabolizes excess hoHomozygous defects of other genes that lead to similarly mocysteine which is not required for methyltransfer and desevere elevations in plasma homocysteine include those enlivers sulfate for the synthesis of heparin, heparan sulfate, coding for methylenetetrahydrfolate reductase (MTHFR) or dermatan sulfate, and chondroitin sulfate. It is important for any of the enzymes which participate in the synthesis of to note that because homocysteine is not a normal dietary methylated vitamin B12. [11] [12] [13] [14] [15] [16] [17] Genetic impairments for the constituent, the sole source of homocysteine is methionine.
Because of the existence of a cellular homocysteine export mechanism, 2,3 plasma normally contains a small amount of Homocysteine metabolic pathways. In the methylation pathway, homocysteine acquires a methyl group either from betaine, a reaction that occurs mainly in the liver or from 5-methyltetrahydrofolate, a reaction which occurs in all tissues and is vitamin B12-dependent. In the transsulfuration pathway homocysteine condenses with serine to form cystathionine in a reaction that is catalyzed by CBS and requires PLP.
vitamin B12-dependent methyltetrahydrofolate:homocysinstances may differ depending on which arm of the two metabolic pathways of homocysteine metabolism is defecteine methyltransferase have not been reported.
4 MTHFR deficiency was first described by Mudd et al 14 in two unretive. 1 An impairment in the remethylation pathway, even if it is mild, will lead to a substantial increase in plasma lated teenagers. In contrast to patients with CBS deficiency, these patients had slightly reduced methionine levels in their homocysteine concentrations under fasting conditions. Such an impairment may be due to inadequate status of either plasma and normal CBS activity in skin fibroblast extracts. Although the hyperhomocysteinemia associated with this defolate or vitamin B12 or to defects in the gene encoding for MTHFR. 1,17,20-33 MTHFR contains flavin adenine dinucleofect is less severe than in homozygous CBS deficiency, the prognosis for these patients is generally worse than in CBS tide (FAD) as a prosthetic group, which raises the possibility that vitamin B2 status is also a determinant of fasting plasma deficiency, 18 related in part to the unresponsiveness to any form of treatment. Most patients with MTHFR deficiency homocysteine levels. In contrast, a mild impairment in the transsulfuration pathway will lead, at most, to a very slight have hypomethioninemia, but in contrast to patients who have hypomethioninemia due to inborn errors of vitamin B12 increase in fasting plasma homocysteine levels. This mild impairment, which may be caused by heterozygous defects metabolism and who develop severe megaloblastic anemia, 19 patients with MTHFR deficiency do not become anemic.
in the CBS gene or inadequate levels of vitamin B6, 1, 20, [34] [35] [36] [37] [38] is normally identified by an abnormal increase in plasma However, expression of MTHFR deficiency is variable 14 (see below).
homocysteine after a methionine loading test or following a meal. 20, [38] [39] [40] [41] The different phenotype anticipated in remethylVitamin B12, an essential nutrient, is converted to methylcobalamin, which functions as a cofactor for methionine ation and transsulfuration defects is supported by studies conducted in vitamin-deficient animal models. Thus, fasting synthase, and to 5-deoxyadenosylcobalamin, the coenzyme for mitochondrial methylmalonyl-CoA mutase. Several displasma homocysteine concentration is 10-fold higher in folate deficient rats than in folate supplemented rats. 42 This tinct genetic defects of cobalamin transport and metabolism resulting in decreased methionine synthase activity and hyhigh concentration of homocysteine in plasma was in part due to a lack of MTHF for homocysteine transmethylation perhomocysteinemia have been described (transcobalamin II deficiency, Cbl C, D, E, and G mutations). These defects and to insufficient S-adenosylmethionine for the activation of the transsulfuration pathway. 42 In both humans and rats, may selectively hamper methylation of vitamin B12. In addition, such defects may impair synthesis of 5-deoxyadenosylmild vitamin B6 deficiency was associated with normal fasting plasma homocysteine levels. Fasting hyperhomocyscobalamin, with resulting methylmalonic aciduria.
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The more common causes of hyperhomocysteinemia are teinemia in vitamin B6 deficiency may occur only if the deficiency is severe and sustained over a long period of also moderate in character and may be caused by less severe defects in genes encoding for enzymes or from inadequate time. 36 After methionine load, the homocysteine concentration increased 35-fold in rats that were vitamin B6-deficient status of those vitamins that are involved in homocysteine metabolism. Plasma homocysteine concentrations in these compared with about fourfold in control rats and less than AID 59 Preliminary evidence indicates that the frequency of homozygotes for the 677CT in the Family Heart Study. 43 Plasma total homocysteine were measured under fasting conditions and 4 hours after a methimutation may vary significantly in populations from different geographic areas (from 1.4% to 15%). 60 In the Dutch populaonine load for each participant. Using homocysteine values greater than the 90th percentile for the definition of hyperhotion, homozygosity for this mutation is 15% and 5% in 60 vascular patients and 111 controls, respectively. 61 In an Italmocysteinemia (both fasting and methionine load), it was shown that of 43 hyperhomocysteinemic individuals, 20 ian patient population with arterial or venous occlusive disease, the prevalence of homozygotes was 19 of 64 individu-(46%) had fasting hyperhomocysteinemia only, 17 (34.5%) had postmethionine load hyperhomoccysteonemia only and als (29.7%). 62 In a control group (n Å 258), on the other hand, homozygosity for the 677CT mutation was only just 7 (14%) had both types of hyperhomocysteinemia.
Existence of an interrelationship between vitamin status 15.1%. Interestingly, none of 7 patients with isolated methionine intolerance was homozygous for the mutation. 63 and plasma homocysteine was first reported by Kang et al, 17 who showed an inverse relationship between homocysteine The impact of MTHFR thermolabile variant on plasma homocysteine levels is as of yet unclear. The hyperhomocysand plasma folate concentrations. Other studies have shown the existence of an inverse correlation between homocysteine teinemia seen in the original patients of Kang et al 17 was associated with low folate plasma levels, and folate suppleand folate or vitamin B12 plasma concentrations and the efficacy of vitamin supplementation in the lowering of mentation reduced homocysteine to normal levels. In the above-mentioned Italian study, 62 18 of the 19 patients who plasma homocysteine levels.
22-24,26-31,33-35,44-51 The independent associations between individual nutrients and homocyswere homozygotes for the 677CT mutation were hyperhomocysteinemic with levels of homocysteine in plasma that were teine concentrations were studied in an established cohort of Americans 52 (The Framingham Heart Study). After conhigher than the 95th percentile in the respective age-matched controls. In a recent study the occurrence of an interaction trolling for age, sex, and other vitamins, nonfasting plasma homocysteine exhibited a strong, nonlinear inverse associabetween MTHFR thermolability genotype and folate status was shown. 64 When plasma folate concentrations were above tion with plasma folate. Minimum levels of homocysteine were observed around 10 nmol/L of folate and above. Nonthe median (15.4 nmol/L), plasma homocysteine levels were low and unrelated to the MTHFR genotype. However, when fasting plasma homocysteine exhibited weaker inverse associations with plasma concentrations of vitamin B12 and pyriplasma folate concentrations were below the median, plasma homocysteine levels were significantly higher in homozydoxal-5-phosphate (PLP, the active form of vitamin B6).
Potential interactions between vitamin status and genetic gotes for the 677CT mutation than in those with the normal genotype. 64 These data imply that the phenotypic expression abnormalities of the enzymes involved in methionine metabolism in the pathogenesis of hyperhomocysteinemia is illusof the MTHFR genotypes is dependent on the availability of folate, suggesting that homozygotes for the thermolabile trated by the recent data on the thermolabile MTHFR, a variant of the enzyme which is caused by a mutation in the genotype might have a higher folate requirement than individuals with a normal genotype. Because FAD is an essential structural gene at a polymorphic site (see below).
prosthetic group for MTHFR activity, it stands to reason that
INTERACTION BETWEEN MTHFR THERMOLABILITY AND
vitamin B2 status is also a determinant of plasma homocys-VITAMIN STATUS teine levels. The latter relationship has yet to be demonstrated in population-based studies. Mutations that result in severely reduced MTHFR activity and hyperhomocysteinemia are rare. [53] [54] [55] However, in 1988
HYPERHOMOCYSTEINEMIA AND THROMBOEMBOLIC Kang et al 17 reported that two unrelated patients with moder-DISEASE ate hyperhomocysteinemia and low folate levels had a variant of MTHFR that was distinguished from the normal enThe relationship between severe hyperhomocysteinemia and arterial disease was first suggested by McCully, 65 who zyme (as measured in lymphocyte extracts) by its lower specific activity (50%) and its thermolability. In subsequent observed autopsy evidence of precocious arterial thrombosis and atherosclerosis in a homocystinuric patient with imstudies, Kang et al 56, 57 showed that MTHFR thermolability is an inherited recessive trait, which is present in approxipaired cobalamin metabolism that was identical to what had earlier been described in homocystinuric patients with CBS mately 5% of the general population and 17% of patients with proven coronary artery disease, but is not associated deficiency. 66 This deficiency in CBS is characterized by arteriosclerosis, thromboembolic complications, skeletal abnorwith neurological complications. Impaired activity of MTHFR, due to the thermolabile form of the enzyme, has malities, ectopia lentis, and mental retardation. In 1976, Wilcken and Wilcken 67 showed that the concentration of been observed in as many as 28% of hyperhomocysteinemic patients with premature vascular disease. 58 The cDNA for homocysteine-cysteine mixed disulfide after a methionine load was slightly higher in coronary heart disease patients human MTHFR has been recently isolated 54 and it has been shown that MTHFR thermolability is caused by a point mutathan in controls, thus providing the first evidence of an association between mild hyperhomocysteinemia and vascular tion (677C to T transition) at a polymorphic site, resulting in a valine substitution for an alanine in this enzyme. 59 The disease. Mildly increased homocysteine levels were later reported in coronary artery disease patients, was independent of the presdifference in fasting and postmethionine load plasma homocysteine levels with age/sex-matched healthy controls. Howence of risk factors like smoking, hyperlipidemia, hypertension, and diabetes. This suggested that hyperhomocysteineever, other investigators have reported a positive association between hyperhomocysteinemia and venous thrombotic outmia is an independent risk factor for the abovementioned clinical conditions. Homocysteine concentrations in patients comes. In one study 94 elevated fasting plasma homocysteine levels were reported in 25% of patients who developed vewith symptomatic vascular disease are on average 31% greater than in normal controls, 87 and prospective assessment nous thrombosis before 60 years of age. Fasting and postmethionine load homocysteine levels were measured by Falcon of vascular disease risk indicates that plasma homocysteine levels are associated with increased risk of myocardial inet al 95 in a series of 80 patients who had at least one verified episode of venous thromboembolism before the age of 40 farction.
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Although venous thromboembolism accounts for 50% of years and were free from hemostatic abnormalities known to be associated with increased risk of venous thromboembothe vascular complications of homocystinuria, 90 the link between less severe hyperhomocysteinemia and venous thromlism. Fasting hyperhomocysteinemia was observed in 8.8% of patients, but postmethionine load hyperhomocysteinemia boembolic disease was overlooked until recently. Recurrent episodes of thromboembolism, events that occur at an early was present in 17.7% of the patients. About half of the patients with hyperhomocysteinemia had a positive family age, thrombosis after trivial provocation, and thrombosis at unusual sites are all features which should heighten the suspihistory of thrombosis and familial hyperhomocysteinemia was confirmed in over 50% of the families studied. In a cion that an inherited metabolic abnormality is playing an etiologic role. 91 Studies on the relationship between thromcross-sectional 2-year evaluation of 157 consecutive unrelated patients with a history of venous or arterial occlusive bosis and mild hyperhomocysteinemia are summarized in Table 1 . Brattstrom et al 92 found no significant difference in disease occurring before the age of 45 years or at unusual sites, moderate hyperhomocysteinemia was detected in plasma homocysteine concentrations between 42 patients with venous thromboembolism and healthy control subjects, 13.1% and 19.2% of patients with venous or arterial occlusive disease. 96 The prevalence of hyperhomocysteinemia was although the male patients showed a tendency of higher plasma homocysteine than male control subjects. Similarly, almost twice as high when based on homocysteine measure-AID for thrombosis and coronary artery disease. During the follow-up there were 29 cases of stroke and 31 arterial thromshown in 8 of the 12 families investigated. Event-free survival analysis showed that the relative risk in patients with botic events. Hyperhomocysteinemia, defined as total plasma homocysteine ú14.1 mmol/L), was found in 15% of these moderate hyperhomocysteinemia and the other defects was 1.7 times greater than in patients without defects and that patients and was significantly associated with arterial thrombotic events (odds ratio 3.74 [95% confidence interval (CI) the risk conferred by hyperhomocysteinemia was similar to that of defects affecting the protein C system. A higher rate 1.96 to 7.13], P Å .0001) and with stroke (odds ratio 2.24 [95% CI 1.22 to 4.13], P Å .01). After adjustment for estabof recurrent thrombosis was also observed in patients with hyperhomocysteinemia and with the other defects than in lished risk factors, hyperhomocysteinemia remained an independent risk factor for thromboses (P Å .05) and stroke (P patients without defects. 97 Homocysteine levels above the 90th percentile of the control distribution were observed in Å .04).
As in the case for deficiencies of the protein C anticoaguanother study in 25% of 185 patients with recurrent venous thrombosis, with a relative risk of recurrence two times lant system, not all patients with hyperhomocysteinemia develop thrombosis. The possibility that factors synergistic to greater in patients with hyperhomocysteinemia than in those without hyperhomocysteinemia. 97 In this study, the relative hyperhomocysteinemia may be required for the development of thrombotic manifestations was explored in 45 members risk of patients with postmethionine load homocysteine concentrations exceeding the 90th percentile (2.6) was similar to of seven unrelated consanguineous kindreds in which at least one member was homozygous for homocystinuria. 101 Thromthat of patients with fasting hyperhomocysteinemia. Twentyseven of the 46 patients with fasting hyperhomocysteinemia bosis occurred in 6 of 11 patients with homocystinuria before the age of 8 years; all 6 patients also had activated protein C also had postload hyperhomocysteinemia, whereas 17 patients had isolated methionine intolerance. Hence, the overall resistance. Conversely, of four patients with homocystinuria who did not have activated protein C resistance, none had prevalence of hyperhomocysteinemia in this patients' population was 34.1%. However, because absolute postmethiothrombosis occurring before the age of 17 years. The investigators concluded that the combination of homocystinuria and nine load values (instead of the postmethionine load above baseline levels) were considered in this study, the relative activated protein C resistance conveys a substantial risk for thrombosis. 102 Such a conclusion may cast doubts about an contribution of remethylation or transsulfuration defects in the risk conferred by hyperhomocysteinemia could not be independent pathogenic role of hyperhomocysteinemia in venous thromboembolism. Both activated protein C resisevaluated.
These data represent strong evidence supporting the role tance and hyperhomocysteinemia are highly prevalent in patients with early onset vascular occlusive disease. 96 If the of moderate hyperhomocysteinemia in the development of premature and/or recurrent venous thromboembolic disease. association of activated protein C resistance and moderate hyperhomocysteinemia markedly increases the thrombotic High plasma homocysteine levels are also a risk factor for deep-vein thrombosis in the general population. Fasting horisk, one would anticipate its prevalence to be significantly higher than expected based on the prevalence of the isolated mocysteine concentrations were measured in 269 patients below 70 years of age with a first episode of deep-vein defects. In a series of 307 patients with early onset venous or arterial disease or with thrombosis occurring at unusual thrombosis and matched control subjects participating in the sites, the prevalence of isolated activated protein C resistance Leiden Thrombophilia Study.
100 Hyperhomocysteinemia exand moderate hyperhomocysteinemia (fasting or postmethioceeding the 95th percentile of the control group was found nine-load) were 10% and 27%, respectively. The combined in 10% of the patients, with a matched odds ratio of 2.5. defect was detected in 3.6% of the patients, a figure slightly, The effect of hyperhomocysteinemia was independent of but not significantly, higher than the 2.7% prevalence exother well-established risk factors for thrombosis, including pected, assuming no effect of the association on the risk of protein C, protein S, and antithrombin III deficiencies and thrombosis. 103 Although other possibilities cannot be ruled activated protein C resistance. An unexpected finding of this out, these data are consistent with the notion that moderate study was the observation that the association between elehyperhomocysteinemia, per se, is an independent risk factor vated homocysteine levels and venous thrombosis was for both venous and arterial thromboembolic disease. stronger among women than among men. Because nutritional parameters were not evaluated in this study, it cannot THROMBOGENIC MECHANISMS OF be ruled out that the stronger association observed in women HYPERHOMOCYSTEINEMIA may be caused by a different vitamin status. In addition, postmethionine load homocysteine measurements were not Despite the large number of studies suggesting that mild carried out, resulting in a potential underestimation of the elevations of homocysteine in plasma are associated with an risk conferred by hyperhomocysteinemia.
increased risk for occlusive vascular disease, thrombosis, Most recently, Petri et al 101 reported a prospective study and stroke, the question of whether homocysteine, per se, is on the association between homocysteine and risk of stroke responsible for these associations remains uncertain. 115, 116 erozygosity for CBS deficiency is not associated with increased risk in heart attacks and stroke. Swift and Morrell
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In vitro studies of cultured endothelial cells also showed a toxic effect of homocysteine on cell viability and function, questioned the validity of some of the methods used by Mudd et al and argued that the data actually point to inbut these studies were conducted using extremely high homocysteine concentrations (1 to 10 mmol), exceeding the creased mortality rates in this heterozygote population. Two studies that used a noninvasive (doppler ultrasound) techlevels encountered even under the most severe pathologic conditions. 114,117-119 Furthermore, at no time did these studies nique also provided conflicting results. Clarke 106 found no evidence of increased frequency of endothelial plaques in show that the observed effect was specific for homocysteine and cannot be observed with other sulfur-containing comthe neck arteries of 25 Irish heterozygotes, compared with 21 control subjects. Rubba et al, 84 on the other hand, indipounds, particularly cysteine, whose concentration in plasma is 20-to 25-fold higher than that of homocysteine. Nonspecated more frequent early vascular lesions in the iliac and internal carotid arteries in 14 heterozygotes than in 47 concific inhibition of prostacyclin synthesis 120 and activation of trols. At the molecular biology level, Kozich et al 107 examfactor V 121 by high concentrations of homocysteine on culined the CBS alleles in four patients with premature occlutured endothelial cells has been reported. Inhibition of prosive arterial disease who were (1) hyperhomocysteinemic tein C activation 122 and downregulation of thrombomodulin based on postmethionine load results, and (2) had lower expression 123 at homocysteine concentrations greater than 5 enzyme activity in their fibroblasts. None of the eight alleles mmol/L have been also observed. One to 5 mmol homocyscontained any mutation which resulted in diminished enzyme teine specifically blocks t-PA, but not plasminogen binding activity. In a prior study this group of investigators showed to endothelial cells. 124 The toxic effect of high homocysteine that cultured fibroblasts are not always reliable for testing concentrations on endothelial cells 125 also results in increased the phenotypic expression in homocystinuric patients. 7 platelet adhesion, 120 impaired regulation of endothelium-deOther studies 61 found that prevalence of the more common rived relaxing factor and related nitrogen oxides, 126 induction CBS mutations is not higher in the patient populations. A of tissue factor, 127 suppression of heparan sulfate expresknockout mouse with CBS deficiency reported by Watanabe sion, 128 and stimulation of smooth muscle cell proliferaet al 108 was found to lack manifestations of thrombosis or/ tion. 129 Hyperhomocysteinemia may induce oxidation of and cardiovascular complications and instead exhibited fatty low-density lipoprotein in vitro. 130 Because homocysteine livers. This is despite the fact that the levels of homocysteine can participate in disulfide bond exchange reactions, it is in plasma were 40-fold higher in the homozygote mice than possible that excessive homocysteine entering the circulation in the control mice. It might be that these mice did not live can alter plasma proteins by this process. It has been reported long enough for cardiovascular complications to develop.
that homocysteine concentrations as low as 8 mmol/L markOther inconsistencies relate to the question of whether edly increases the affinity of Lp(a) for plasmin modified MTHFR thermolability confers increased risk for the various fibrin surfaces, thus inhibiting plasminogen activation. 131 diseases. The early study by Kang et al, 57 who relied on It is generally held that different mechanisms are responsienzyme activity, has shown a higher prevalence (17%) of ble for arterial and venous thromboembolic diseases, involvthis variant in a North American, coronary artery disease ing platelet function abnormalities in arterial thrombosis and (CAD) population than in normal healthy controls (5%).
abnormalities of coagulation and/or fibrinolysis in venous Similarly, the abovementioned studies, which relied on mothromboembolism. Ex vivo studies looking for such abnorlecular biology techniques, demonstrated higher prevalence malities in patients with hyperhomocysteinemia have given of the 677CT homozygotes in vascular disease patients inconclusive results. 115, 116, [132] [133] [134] [135] [136] [137] In subjects with severe hy-(15%) than in controls (5%) in a Dutch population; and to perhomocysteinemia caused by homozygous CBS defi-29.7% in an Italian patient population, compared with only ciency, an abnormally high in vivo biosynthesis of throm-15.1% in healthy controls. 61, 62 boxane A 2 -as reflected by the urinary excretion of its major However, other studies have been contradictory. No difmetabolite 11-dehydro-thromboxane B 2 -has been obference in the prevalence of the homozygosity for the 677CT served. 138 Administration of aspirin inhibits thromboxane mutation was found between coronary patients and controls production; urinary appearance returns to baseline levels in an Australian population, 109 a second Dutch population, 110 over a time course consistent with platelet survival, suga French Canadian population, 111 a British population, 112 and gesting platelets are the major source of increased thromboxin the Physician Health Study. 113 ane urinary excretion. 138 Because thrombin is a potent inThese apparent inconsistencies can be explained on the ducer of platelet activation, the presence of hypercoagulable basis of the differences in the study population, both with state was investigated in homocystinuric patients. 139 Inrespect to genetic background and dietary habits, differences creased levels of prothrombin fragment 1.2, thrombin-antiin the pathology among species (eg, human beings v mice), thrombin complex, and activated protein C were all observed and others. It is for these reasons that understanding the in homocystinuric patients on vitamin treatment who were mechanism that underlies this relationship between homofree of vascular disease. However, these abnormalities did cysteine and disease is of primary importance. What follows not correlate with urinary thromboxane excretion. Interestis a brief summary of this effort.
ingly, protein C levels, but not factor VII and factor II levels, Early animal studies suggested a toxic effect of hyperhowere significantly reduced in homocystinuric patients and correlated with the degree of hyperhomocysteinemia. 
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Diet-responsive deficiency of factor VII was previously reis a primary determinant of mild to moderate hyperhomocysported in CBS-deficient patients.
134,135,140 Reduced protein C teinemia accounting for approximately two thirds of all such levels may at least partly contribute to venous thrombotic cases. 50 Vitamin supplementation results in near normalizamanifestations of patients with homozygous CBS deficiency.
tion of plasma homocysteine in most cases. 145, 146 A recent The observation that the increased urinary thromboxane exmeta-analysis of 38 studies evaluated the risk of hyperhomocretion was independent of homocysteine levels and was cysteinemia for arteriosclerotic vascular disease, estimated present both in vitamin B6-responsive and nonresponsive the reduction of homocysteine levels by folic acid adminispatients may have an impact on treatment of hyperhomocystration, and calculated the potential reduction of coronary teinemia. 139 It is noteworthy that although the effectiveness artery disease mortality by increasing folic acid intake.
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of vitamin B6 in preventing thromboembolism in pyridoxThese analyses proposed that elevations of total homocysine-responsive patients was shown to be statistically highly teine were an independent graded risk factor for arteriosclesignificant, the occurrence of thromboembolism was not rotic vascular disease and calculated that folic acid fortificaabolished by vitamin supplementation. 19 tion of food would reduce the annual mortality by 50,000. A recent study by Lentz et al 141 used a cymonologus monVitamin supplementation may also reduce recurrence of vekey model to investigate possible mechanisms of action of nous thromboembolic disease in patients with hyperhomomild hyperhomocysteinemia. Mild hyperhomocysteinemia cysteinemia. However, at present the clinical efficacy of this was induced by a diet high in methionine, depleted of folate, approach has not been tested. In addition, the bulk of eviand free of choline. Total homocysteine concentrations were dence indicates that fasting total homocysteine determina-10.6 mmol/L in the experimental monkeys and 4.0 mmol/L tions may identify up to 50% of the total population of in the control group. In response to activation of platelets hyperhomocysteinemic subjects. Patients with isolated meby infusion of collagen, blood flow to the leg decreased thionine intolerance may benefit from vitamin B6 suppleby 42% compared with 14% in controls. The response of mentation. resistance vessels to the endothelium-dependent vasodila-
The time is ripe for a placebo/controlled multicenter trial tors, adenosine diphosphate (ADP) and acetylcholine, were for determining the efficacy of vitamin supplementation in markedly impaired in hyperhomocysteinemic monkeys, the reduction of morbidity and mortality among patients with which indicates that increased vasoconstriction in response occlusive vascular disease, stroke, and thrombosis. Because to collagen may be caused by decreased vasodilator responvitamins are relatively inexpensive, there is little incentive siveness to platelet-generated ADP. Furthermore, thrombofrom the part of drug companies to support such a trial and modulin anticoagulant activity in aorta decreased by 34% in the hyperhomocysteinemic monkeys.
it is up to government agencies to assume this task. For these Another recent study with promising results showed that reasons it is important that the design of such a trial take incubation of aortic endothelial cells with 50 mmol/L homointo account all the information available. Homocysteine mecysteine for 4 hours led to 64% reduction in the level of tabolism requires the participation of folate as well as vitaglutathione peroxidase.
142 Glutathione peroxidase is a key min B12 and vitamin B6 coenzymes. Reduction of homocysenzyme in the oxidative defense mechanism which was teine levels in plasma requires that all three of these vitamins shown to potentiate the action of nitric oxide. These observaare supplemented. tions indicate that homocysteine may cause endothelial cell injury both by promoting the formation of peroxides as well 
